5-吡咯烷酮-3-甲酸甲酯 | 35309-35-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 5-吡咯烷酮-3-甲酸甲酯
• 中文别名: 5-氧代吡咯烷-3-甲酸甲酯
• 英文名称: methyl 5-oxopyrrolidine-3-carboxylate
• 英文别名: methyl 5-pyrrolidone-3-carboxylate
• CAS: 35309-35-4
• 化学式: C₆H₉NO₃
• mdl: MFCD08275678
• 分子量: 143.142
• InChiKey: FJRTVLWHONLTLA-UHFFFAOYSA-N

物化性质

• 熔点：
  62-64 °C
• 沸点：
  132-142 °C(Press: 0.45 Torr)
• 密度：
  1.204
• 溶解度：
  可溶于氯仿（轻微）、甲醇（轻微、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933790090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-oxopyrrolidine-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-oxopyrrolidine-3-carboxylate
CAS number: 35309-35-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NO3
Molecular weight: 143.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-吡咯烷酮-3-甲酸甲酯 在 sodium tetrahydroborate 、 三氟化硼乙醚 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.17h， 生成 1-Boc-3-羟甲基吡咯烷
  参考文献：
  名称：

  N-Boc-3-吡咯烷甲醛的合成方法

  摘要：

  本发明公开了一种N‑Boc‑3‑吡咯烷甲醛的合成方法，该方法以衣康酸二甲酯为原料，经过分子内环化反应得到5‑氧‑3‑吡咯烷羧酸甲酯；然后经过还原反应得到吡咯烷‑3‑甲醇，再经过Boc保护得到N‑Boc‑吡咯烷‑3‑甲醇，最后经过氧化反应得到最终产品化合物；本方法操作简单方便，成本低廉，含量>99%，对环境污染很小，适合工业化生产。

  公开号：

  CN106588738B
• 作为产物：
  描述：

  衣康酸二甲酯 在 氯化铵 、 三乙胺 作用下， 以 甲醇 为溶剂， 以60%的产率得到5-吡咯烷酮-3-甲酸甲酯
  参考文献：
  名称：

  化学合成对映体纯的对羟基乙酸甲酯的氮杂类似物和甲基β-脯氨酸的两种对映体的化学酶法

  摘要：

  通过酶促拆分相应的手性外消旋混合物，获得1-烷基-5-氧代-3-吡咯烷羧酸的对映体纯甲酯。在1-苄基衍生物和α-胰凝乳蛋白酶之间观察到特别有利的相互作用，这也得到分子力学计算的支持，其对映体比率E超过200。内酰胺的绝对构型是通过CD光谱法确定的。从所得对映体纯的（99％ee）（S）-（+）-1-苄基-3-吡咯烷羧酸和（R）-（-）-1-苄基-3-吡咯烷甲酸甲酯，（+ ）和（-）-β-脯氨酸的合成产率分别为99％ee和18％和22％。

  DOI：

  10.1016/s0957-4166(01)00523-7

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• [EN] 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES<br/>[FR] COMPOSÉS DE 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018011160A1

  公开（公告）日：2018-01-18

  The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

  本发明涉及式(I)化合物或药用可接受的盐、对映异构体或非对映异构体，其中R1至R4如上所述。这些化合物可能用于治疗或预防乙型肝炎病毒感染。
• [EN] AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS<br/>[FR] COMPOSÉS D'AZAINDAZOLE EN TANT QU'INHIBITEURS DE LA T790M CONTENANT DES MUTANTS DE L'EGFR
  申请人：GENENTECH INC

  公开号：WO2014210354A1

  公开（公告）日：2014-12-31

  This invention relates to novel compounds of formula (I), which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

  这项发明涉及公式（I）的新化合物，这些化合物是T790M含有EGFR突变体的抑制剂，涉及含有它们的药物组合物，它们的制备过程，以及它们在预防或治疗癌症中的应用。